Which has better valuation and earnings, FULC or KLRS?

Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fulcrum Therapeutics N/A N/A -$74.88M -$1.21 N/A Kalaris Therapeutics N/A N/A -$43.44M -$2.02 N/A

Is FULC or KLRS more profitable?

Fulcrum Therapeutics' return on equity of -25.38% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Fulcrum Therapeutics N/A -25.38% -24.15% Kalaris Therapeutics N/A -71.71% -42.95%

Which has preferable earnings and valuation, GLSI or KLRS?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenwich LifeSciences N/A N/A -$19.36M -$1.54 N/A Kalaris Therapeutics N/A N/A -$43.44M -$2.02 N/A

Is GLSI or KLRS more profitable?

Kalaris Therapeutics' return on equity of -71.71% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Greenwich LifeSciences N/A -793.81% -295.32% Kalaris Therapeutics N/A -71.71% -42.95%

Which has stronger earnings and valuation, IMRX or KLRS?

Immuneering is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.04 N/A Kalaris Therapeutics N/A N/A -$43.44M -$2.02 N/A

Is IMRX or KLRS more profitable?

Immuneering's return on equity of -27.15% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -27.15% -25.75% Kalaris Therapeutics N/A -71.71% -42.95%

Is KLRS or PYXS more profitable?

Kalaris Therapeutics' return on equity of -71.71% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -71.71% -42.95% Pyxis Oncology N/A -215.23% -112.19%

Kalaris Therapeutics (KLRS) Competitors

$3.12 -0.12 (-3.70%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$3.20 +0.08 (+2.53%)

As of 09/23/2026 07:40 PM Eastern

Compare

KLRS vs. FULC, GLSI, IMRX, PYXS, and CUE

Should you buy Kalaris Therapeutics stock or one of its competitors? Kalaris Therapeutics's main competitors and comparable companies include Fulcrum Therapeutics (FULC), Greenwich LifeSciences (GLSI), Immuneering (IMRX), Pyxis Oncology (PYXS), and Cue Biopharma (CUE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kalaris Therapeutics compare to Fulcrum Therapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

In the previous week, Fulcrum Therapeutics had 6 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 6 mentions for Fulcrum Therapeutics and 0 mentions for Kalaris Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.26 beat Kalaris Therapeutics' score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Fulcrum Therapeutics	Neutral
Kalaris Therapeutics	Neutral

Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	N/A	N/A	-$74.88M	-$1.21	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A

89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 7.3% of Fulcrum Therapeutics shares are held by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Fulcrum Therapeutics' return on equity of -25.38% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-25.38%	-24.15%
Kalaris Therapeutics	N/A	-71.71%	-42.95%

Fulcrum Therapeutics has a beta of 2.59, meaning that its stock price is 159% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market.

Fulcrum Therapeutics presently has a consensus target price of $8.20, suggesting a potential upside of 115.22%. Kalaris Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 500.96%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kalaris Therapeutics is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Fulcrum Therapeutics beats Kalaris Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Greenwich LifeSciences?

Greenwich LifeSciences (NASDAQ:GLSI) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Kalaris Therapeutics' return on equity of -71.71% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-793.81%	-295.32%
Kalaris Therapeutics	N/A	-71.71%	-42.95%

Greenwich LifeSciences presently has a consensus target price of $69.00, suggesting a potential upside of 294.06%. Kalaris Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 500.96%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kalaris Therapeutics is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Greenwich LifeSciences has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market.

In the previous week, Kalaris Therapeutics' average media sentiment score of 0.00 beat Greenwich LifeSciences' score of -1.32 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Greenwich LifeSciences	Negative
Kalaris Therapeutics	Neutral

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.54	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A

Summary

Kalaris Therapeutics beats Greenwich LifeSciences on 9 of the 12 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Immuneering?

Immuneering (NASDAQ:IMRX) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Immuneering is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A

Immuneering currently has a consensus price target of $17.50, indicating a potential upside of 299.54%. Kalaris Therapeutics has a consensus price target of $18.75, indicating a potential upside of 500.96%. Given Kalaris Therapeutics' higher probable upside, analysts clearly believe Kalaris Therapeutics is more favorable than Immuneering.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Immuneering's return on equity of -27.15% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-27.15%	-25.75%
Kalaris Therapeutics	N/A	-71.71%	-42.95%

Immuneering has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market.

67.7% of Immuneering shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 14.9% of Immuneering shares are held by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Immuneering's average media sentiment score of 0.00 equaled Kalaris Therapeutics'average media sentiment score.

Company	Overall Sentiment
Immuneering	Neutral
Kalaris Therapeutics	Neutral

Summary

Immuneering beats Kalaris Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Pyxis Oncology?

Kalaris Therapeutics (NASDAQ:KLRS) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Kalaris Therapeutics presently has a consensus price target of $18.75, indicating a potential upside of 500.96%. Pyxis Oncology has a consensus price target of $8.75, indicating a potential upside of 171.74%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Kalaris Therapeutics is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Kalaris Therapeutics' return on equity of -71.71% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-71.71%	-42.95%
Pyxis Oncology	N/A	-215.23%	-112.19%

In the previous week, Pyxis Oncology had 2 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 2 mentions for Pyxis Oncology and 0 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.00 equaled Pyxis Oncology'saverage media sentiment score.

Company	Overall Sentiment
Kalaris Therapeutics	Neutral
Pyxis Oncology	Neutral

Kalaris Therapeutics has higher earnings, but lower revenue than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A
Pyxis Oncology	$13.86M	19.38	-$79.62M	-$1.41	N/A

66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by company insiders. Comparatively, 5.7% of Pyxis Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kalaris Therapeutics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market.

Summary

Kalaris Therapeutics beats Pyxis Oncology on 8 of the 13 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Cue Biopharma?

Kalaris Therapeutics (NASDAQ:KLRS) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by company insiders. Comparatively, 14.6% of Cue Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kalaris Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.45, indicating that its share price is 145% more volatile than the broader market.

Kalaris Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -435.83%. Kalaris Therapeutics' return on equity of -71.71% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-71.71%	-42.95%
Cue Biopharma	-435.83%	-620.06%	-291.15%

Kalaris Therapeutics currently has a consensus price target of $18.75, indicating a potential upside of 500.96%. Cue Biopharma has a consensus price target of $83.00, indicating a potential upside of 161.75%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Kalaris Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Cue Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cue Biopharma had 17 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 17 mentions for Cue Biopharma and 0 mentions for Kalaris Therapeutics. Cue Biopharma's average media sentiment score of 0.68 beat Kalaris Therapeutics' score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Kalaris Therapeutics	Neutral
Cue Biopharma	Positive

Cue Biopharma has higher revenue and earnings than Kalaris Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A
Cue Biopharma	$37.66M	6.12	-$26.60M	-$27.02	N/A

Summary

Kalaris Therapeutics beats Cue Biopharma on 9 of the 15 factors compared between the two stocks.

Get Kalaris Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KLRS vs. The Competition

Export

Metric	Kalaris Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$77.13M	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-1.54	13.88	274.01	25.69
Price / Sales	N/A	1,382.00	656.83	89.15
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.74	15.30	10.44	6.32
Net Income	-$43.44M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-1.27%	-1.71%	-0.66%	0.17%
1 Month Performance	-23.90%	-6.17%	-3.16%	-3.27%
1 Year Performance	-31.13%	30.64%	15.15%	5.58%

Kalaris Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KLRS Kalaris Therapeutics	2.7668 of 5 stars	$3.12 -3.7%	$18.75 +501.0%	-34.6%	$77.13M	N/A	N/A	110
FULC Fulcrum Therapeutics	2.4261 of 5 stars	$3.79 +0.4%	$8.20 +116.6%	-48.2%	$288.78M	N/A	N/A	55
GLSI Greenwich LifeSciences	2.0514 of 5 stars	$19.47 +5.9%	$69.00 +254.3%	+59.5%	$287.60M	N/A	N/A	13	Negative News
IMRX Immuneering	2.4433 of 5 stars	$4.45 -0.3%	$17.50 +293.7%	-49.0%	$286.22M	N/A	N/A	57	Analyst Forecast
PYXS Pyxis Oncology	2.7656 of 5 stars	$3.39 -0.7%	$8.75 +158.5%	+47.0%	$282.34M	$11.04M	N/A	56

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KLRS) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kalaris Therapeutics (KLRS) Competitors

KLRS vs. FULC, GLSI, IMRX, PYXS, and CUE

How does Kalaris Therapeutics compare to Fulcrum Therapeutics?

Summary

How does Kalaris Therapeutics compare to Greenwich LifeSciences?

Summary

How does Kalaris Therapeutics compare to Immuneering?

Summary

How does Kalaris Therapeutics compare to Pyxis Oncology?

Summary

How does Kalaris Therapeutics compare to Cue Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS vs. The Competition

Kalaris Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kalaris Therapeutics (KLRS) Competitors

KLRS vs. FULC, GLSI, IMRX, PYXS, and CUE

How does Kalaris Therapeutics compare to Fulcrum Therapeutics?

Does the media refer more to FULC or KLRS?

Which has better valuation and earnings, FULC or KLRS?

Do insiders and institutionals believe in FULC or KLRS?

Is FULC or KLRS more profitable?

Which has more volatility & risk, FULC or KLRS?

Do analysts rate FULC or KLRS?

Summary

How does Kalaris Therapeutics compare to Greenwich LifeSciences?

Is GLSI or KLRS more profitable?

Do analysts recommend GLSI or KLRS?

Do institutionals & insiders hold more shares of GLSI or KLRS?

Which has more volatility & risk, GLSI or KLRS?

Does the media favor GLSI or KLRS?

Which has preferable earnings and valuation, GLSI or KLRS?

Summary

How does Kalaris Therapeutics compare to Immuneering?

Which has stronger earnings and valuation, IMRX or KLRS?

Do analysts recommend IMRX or KLRS?

Is IMRX or KLRS more profitable?

Which has more volatility and risk, IMRX or KLRS?

Do institutionals and insiders have more ownership in IMRX or KLRS?

Does the media refer more to IMRX or KLRS?

Summary

How does Kalaris Therapeutics compare to Pyxis Oncology?

Do analysts prefer KLRS or PYXS?

Is KLRS or PYXS more profitable?

Does the media prefer KLRS or PYXS?

Which has higher valuation and earnings, KLRS or PYXS?

Do institutionals and insiders have more ownership in KLRS or PYXS?

Which has more risk and volatility, KLRS or PYXS?

Summary

How does Kalaris Therapeutics compare to Cue Biopharma?

Do institutionals and insiders believe in KLRS or CUE?

Which has more volatility & risk, KLRS or CUE?

Is KLRS or CUE more profitable?

Do analysts prefer KLRS or CUE?

Does the media refer more to KLRS or CUE?

Which has preferable valuation & earnings, KLRS or CUE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS vs. The Competition

Kalaris Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools